We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

This study has been terminated.
(Prevalence of H Pylori in the study population was much lower than anticipated)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00664209
First Posted: April 22, 2008
Last Update Posted: December 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Michael J. Fox Foundation for Parkinson's Research
Information provided by (Responsible Party):
Jeff Bronstein, University of California, Los Angeles
  Purpose
The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.

Condition Intervention Phase
Parkinson's Disease Helicobacter Infections Motor Fluctuations Drug: clartihromycin, amoxicillin, and omeprazole Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease

Resource links provided by NLM:


Further study details as provided by Jeff Bronstein, University of California, Los Angeles:

Primary Outcome Measures:
  • "Off" Time [ Time Frame: 2 months ]
    Average total daily "off" time (measured by patient symptom diaries) in hours


Secondary Outcome Measures:
  • Improvement in UPDRS Total Scores [ Time Frame: 2 months ]
    The Unified Parkinson Disease Rating Scale (UPDRS) is a rating tool to follow the longitudinal course of Parkinson's Disease. It is made up of the 1) Mentation, Behavior, and Mood, 2) ADL and 3) Motor sections. These are evaluated by interview. Some sections require multiple grades assigned to each extremity. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.

  • Improvement in UDPRS Part III [ Time Frame: 2 months ]
    Improvement in UDPRS Part III (Motor) scores ("on" and "off") UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement

  • Improvement in Quality of Life as Assessed by PDQ-39 [ Time Frame: 2 months ]
    The Parkinson's Disease Questionnaire (PDQ)-39 contains 39 questions addressing how often patients have experienced difficulties due to having PD in the preceding month. Items are scored from 0 (never) to 4 (always). Lower scores indicate better quality of life.

  • Participants With Side Effects From Study Treatment [ Time Frame: 2 months ]
    Side effects profile


Enrollment: 64
Study Start Date: January 2008
Study Completion Date: June 2012
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active-placebo
These subject receive treatment with active triple therapy followed by treatment with placebo therapy.
Drug: clartihromycin, amoxicillin, and omeprazole
clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
Other Name: Biaxin, Prilosec
Drug: placebo
placebo therapy
Placebo-active
These subject receive treatment with placebo therapy followed by treatment with active triple therapy.
Drug: clartihromycin, amoxicillin, and omeprazole
clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
Other Name: Biaxin, Prilosec
Drug: placebo
placebo therapy

Detailed Description:
Previous investigations have demonstrated that treatment of Helicobacter pylori with antibiotics leads to improved absorption and pharmacokinetics of levodopa. This may potentially benefit patients with Parkinson's disease who have motor fluctuations, specifically excessive "off" time, when their levodopa is not working to control symptoms. We seek to identify the frequency of H. pylori infection in this population using standard lab assays and determine whether eradication with standard triple therapy results in improved clinical response to medication.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Adults diagnosed with idiopathic Parkinson's disease, Hoehn & Yahr stage 2-4 in the "off" state, with no other concomitant neurologic diseases.
  • Stable (≥30 days) Parkinson's disease therapy, with demonstrable medication efficacy, but with wearing off phenomenon present between levodopa doses (average off time ≥3 hours off time/day).
  • Levodopa therapy required; Any formulation (e.g. Sinemet, Sinemet CR, Stalevo) is acceptable. Parkinson's disease treatment may also include any of the following medications or classes: non-ergot dopamine agonists, COMT inhibitors, MAO-B inhibitors, amantadine, anticholinergics.
  • Positive for H. pylori IgG Ab by serum ELISA (before inclusion in randomized treatment arms).

Exclusion criteria:

  • Current abdominal pain, unexplained nausea/vomiting, or gastrointestinal bleeding.
  • History of gastric cancer, peptic ulcer, duodenal ulcer, or other gastric or duodenal lesions.
  • History of previous gastric surgery.
  • History of previous brain surgery for Parkinson's disease.
  • Family history of gastric cancer.
  • Prior treatment for H. pylori+ status.
  • Recent use (previous 4 weeks) of proton-pump inhibitor, amoxicillin, or clarithromycin.
  • Allergy or sensitivity to penicillin, amoxicillin, clarithromycin, or omeprazole.
  • Use of drugs affecting gastric motility (e.g. domperidone, metoclopramide).
  • Inability to tolerate or participate in testing in the morning in an "off" state.
  • Inability to communicate effectively with study personnel in English.
  • Pregnancy.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00664209


Locations
United States, California
UCLA Neurology
Los Angeles, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
Michael J. Fox Foundation for Parkinson's Research
Investigators
Principal Investigator: Jeff M Bronstein, MD, PhD UCLA Neurology
  More Information

Publications:
Responsible Party: Jeff Bronstein, Professor of Neurology, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00664209     History of Changes
Other Study ID Numbers: MJJF Clinical Discovery 2007
441437-JB-58330
First Submitted: April 21, 2008
First Posted: April 22, 2008
Results First Submitted: October 31, 2017
Results First Posted: December 1, 2017
Last Update Posted: December 1, 2017
Last Verified: October 2017

Keywords provided by Jeff Bronstein, University of California, Los Angeles:
Parkinson's disease
levodopa
Helicobacter pylori

Additional relevant MeSH terms:
Parkinson Disease
Helicobacter Infections
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Gram-Negative Bacterial Infections
Bacterial Infections
Amoxicillin
Omeprazole
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action